Sedor John A 4
4 · CPEX Pharmaceuticals, Inc. · Filed Apr 7, 2011
Insider Transaction Report
Form 4
Sedor John A
DirectorCEO & President
Transactions
- Exercise/Conversion
Common Stock
2011-04-05+146,875→ 165,522 total - Exercise/Conversion
Stock Option (right to buy)
2011-04-05−100,000→ 0 totalExercise: $17.20Exp: 2018-07-01→ Common Stock (100,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2011-04-05−4,375→ 0 totalExercise: $10.00Exp: 2019-09-29→ Common Stock (4,375 underlying) - Tax Payment
Common Stock
2011-04-05$27.25/sh−80,895$2,204,389→ 84,627 total - Disposition to Issuer
Common Stock
2011-04-05−84,627→ 0 total - Disposition to Issuer
Common Stock
2011-04-05−1,200→ 0 total(indirect: By Children) - Exercise/Conversion
Stock Option (right to buy)
2011-04-05−15,000→ 0 totalExercise: $9.88Exp: 2015-08-27→ Common Stock (15,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2011-04-05−20,000→ 0 totalExercise: $10.57Exp: 2016-05-23→ Common Stock (20,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2011-04-05−7,500→ 0 totalExercise: $10.74Exp: 2017-05-23→ Common Stock (7,500 underlying)
Footnotes (4)
- [F1]15,000 options had an exercise price of $9.8762, 20,000 options had an exercise price of $10.5720, 7,500 options had an exercise price of $10.7426, 100,000 options had an exercise price of $17.2050 and 4,375 options had an exercise price of $10.000
- [F2]Pursuant to the Agreement and Plan of Merger between CPEX Pharmaceuticals, Inc., FCB I Holdings inc. and FCB I Acquisition Corp. dated January 3, 2011 (the "Merger Agreement"), each share of CPEX common stock was exchanged for $27.25
- [F3]The reporting person disclaims beneficial ownership of the shares held by his children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose.
- [F4]This option is fully-vested.